finanzen.net
13.06.2019 13:30
Bewerten
(0)

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants

DRUCKEN

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases

MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders.

In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritability of genetic disease1. Meanwhile, several studies have demonstrated that these missing variants can be discovered routinely using highly accurate long reads (HiFi reads) generated by the PacBio® Sequel II® System2,3. A review article from scientists at Radboud University Medical Center summarizes many of these findings, including genetic discovery results for ALS, Huntington’s disease, Parkinsonism, epilepsy, ataxias, myotonic dystrophy, and Fragile X disorders4.

For example, scientists in Japan turned to SMRT Sequencing to explain a familial form of epilepsy that had not been solved with whole exome sequencing. PacBio whole genome sequencing data allowed the team to detect more than 17,000 SVs and quickly identify the 12.4 kb deletion responsible for the family’s condition5.  The team determined that "long-read sequencing ensures unbiased coverage even in GC-rich repetitive sequences, which enables the identification of previously unidentified pathogenic SVs.”

"Far too many genetic diseases have gone unsolved in the genomic era, and it’s becoming clear that some of the answers were simply not conducive to detection with previous technologies,” said Jonas Korlach, Chief Scientific Officer of Pacific Biosciences. "It’s been tremendously gratifying to see the flurry of recent publications reporting the discovery of underlying causes for some of these diseases through the use of SMRT Sequencing systems.”

Additional studies describing novel disease-causing variant detection with SMRT Sequencing will be presented at the European Society of Human Genetics (ESHG) 2019 Annual Meeting, taking place June 15-18 in Gothenburg, Sweden. To learn more, please visit PacBio in ESHG booth #560 or download a flyer with a list of featured presentations at: https://www.pacb.com/wp-content/uploads/2019-ESHG-Program-Flyer.pdf.

References

  1. Chaisson, M. J. P., et al. (2019) Multi-platform discovery of haplotype-resolved structural variation in human genomes. Nature Communications, 10(1), 1784.
     
  2. Wenger, A. M., et al. (2019) Highly-accurate long-read sequencing improves variant detection and assembly of a human genome. bioRxiv, doi:10.1101/519025.
     
  3. Vollger, M. R., et al. (2019) Improved assembly and variant detection of a haploid human genome using single-molecule, high-fidelity long reads. bioRxiv, doi:10.1101/635037.
     
  4. Mantere, T., et al. (2019) Long-read sequencing emerging in medical genetics. Frontiers in Genetics, 10, 426.
     
  5. Mizuguchi, T., et al. (2019) A 12-kb structural variation in progressive myoclonic epilepsy was newly identified by long-read whole-genome sequencing. Journal of Human Genetics, 64, 359–368.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the attributes of the Sequel II System, the future availability, uses, accuracy, quality or performance of, or benefits of using, products or technologies, the suitability or utility of methods, products or technologies for particular applications, studies or projects, the importance of long-read sequencing data, the expected benefits of sequencing projects, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

Nachrichten zu Pacific Biosciences of California Inc

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Pacific Biosciences of California Inc

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
19.10.2018Pacific Biosciences of California OutperformCowen and Company, LLC
03.11.2017Pacific Biosciences of California Equal-WeightFirst Analysis Securities
03.11.2016Pacific Biosciences of California BuyCantor Fitzgerald
15.04.2016Pacific Biosciences of California OverweightFirst Analysis Securities
04.02.2015Pacific Biosciences of California BuyMaxim Group
19.10.2018Pacific Biosciences of California OutperformCowen and Company, LLC
03.11.2016Pacific Biosciences of California BuyCantor Fitzgerald
15.04.2016Pacific Biosciences of California OverweightFirst Analysis Securities
04.02.2015Pacific Biosciences of California BuyMaxim Group
03.11.2017Pacific Biosciences of California Equal-WeightFirst Analysis Securities
17.03.2011Pacific Biosciences of California performOppenheimer & Co. Inc.

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pacific Biosciences of California Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen

Technische Marktanalyse

Wie geht's an der Börse weiter? Setzt sich der Zick-Zack-Kurs fort oder geht es demnächst kräftig nach unten? Am Montag ab 18 Uhr analysiert Achim Matzke die Situation bei Dax, Dow und Co. Jetzt kostenlos anmelden!

Meistgelesene Pacific Biosciences of California News

Keine Nachrichten gefunden.
Weitere Pacific Biosciences of California News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Pacific Biosciences of California Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

Börsen in Fernost zurückhaltend -- Lufthansa mit Gewinnwarnung für 2019 -- Fusion von Sprint und T-Mobile dürfte wohl genehmigt werden -- BASF baut 2019 Stellen ab

BVB will offenbar Mats Hummels zurückholen. 420.000 VW-Kunden nehmen an Musterfeststellungsklage teil. Knorr-Bremse sucht neuen Chef extern. Boeing erhält Milliardenauftrag von US Air Force. Kurzfristiges Darlehen für TOM TAILOR. Bitcoin steigt wieder über 9.000 Dollar. Deutsche Bank plant angeblich milliardenschwere Bad Bank.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
mehr Top Rankings

Umfrage

Sind Sie an einem Investment in die Cannabis-Branche interessiert?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Scout24 AGA12DM8
Wirecard AG747206
Daimler AG710000
Amazon906866
Apple Inc.865985
NEL ASAA0B733
TeslaA1CX3T
Beyond MeatA2N7XQ
Allianz840400
BASFBASF11
Infineon AG623100
BMW AG519000
E.ON SEENAG99